Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
INCY	INCYTE CORP	United States	$12.00B	224,526,128	79.30%	20.70%	Net Selling	Net Buying
HRMY	HARMONY BIOSCIENCES HOLDINGS INC	United States	$1.68B	56,769,081	61.03%	38.97%	Net Selling	Net Selling
VYGR	VOYAGER THERAPEUTICS INC	United States	$447.44M	54,300,627	47.14%	52.86%	Net Selling	Net Selling
AMLX	AMYLYX PHARMACEUTICALS INC	United States	$140.31M	67,782,139	52.71%	47.29%	Net Buying	Net Selling
UTHR	UNITED THERAPEUTICS CORP	United States	$11.06B	47,058,545	87.59%	12.41%	Net Selling	Net Selling
CORT	CORCEPT THERAPEUTICS INC	United States	$2.40B	103,517,388	30.65%	69.35%	Net Buying	Net Buying
EXEL	EXELIXIS INC	United States	$6.88B	303,194,259	85.28%	4.07%	Net Selling	Net Buying
PBYI	PUMA BIOTECHNOLOGY INC	United States	$257.91M	48,207,162	55.20%	44.43%	Net Selling
HALO	HALOZYME THERAPEUTICS INC	United States	$4.91B	126,824,800	78.23%	21.77%	Net Selling	Net Selling
RPRX	ROYALTY PHARMA PLC	United States	$16.88B	597,434,791	51.02%	16.51%	Net Selling	Net Buying
ROIV	ROIVANT SCIENCES LTD	Bermuda	$8.74B	805,846,006	40.14%	59.86%	Net Selling	Net Selling
GMAB	GENMAB A	Denmark	$19.50B	66,074,535	70.53%	0.00%
MDXG	MIMEDX GROUP INC	United States	$933.19M	146,958,420	42.42%	57.58%	Net Buying	Net Selling
BMRN	BIOMARIN PHARMACEUTICAL INC	United States	$17.27B	188,675,622	98.08%	1.63%	Net Selling	Net Selling
MEIP	MEI PHARMA INC	United States	$21.65M	6,662,857	17.91%	82.09%	Net Buying
TGTX	TG THERAPEUTICS INC	United States	$2.17B	154,420,772	53.78%	46.22%	Net Selling	Net Selling
VNDA	VANDA PHARMACEUTICALS INC	United States	$233.60M	57,537,499	56.23%	43.77%	Net Selling	Net Selling
BNTX	BIONTECH SE	Germany	$20.89B	237,725,735	17.05%	0.00%
DBVT	DBV TECHNOLOGIES SA	France	$134.04M	96,431,770	39.10%	15.37%	Net Buying	Net Buying
PLX	PROTALIX BIOTHERAPEUTICS INC	Israel	$83.28M	73,052,124	6.75%	93.25%	Net Buying
SPRO	SPERO THERAPEUTICS INC	United States	$82.42M	53,869,139	25.60%	64.13%	Net Selling	Net Selling
AVRO	AVROBIO INC	United States	$56.52M	44,860,515	46.76%	53.24%	Net Selling	Net Selling
BNOX	BIONOMICS LIMITED	Australia	$11.31M	1,924,808,444	0.07%	0.00%
CRSP	CRISPR THERAPEUTICS AG	Switzerland	$4.71B	80,275,950	62.44%	37.56%	Net Buying	Net Buying
CPRX	CATALYST PHARMACEUTICALS INC	United States	$1.81B	117,863,258	71.64%	16.33%	Net Buying	Net Buying
KNSA	KINIKSA PHARMACEUTICALS LTD	Bermuda	$1.23B	70,615,022	48.48%	9.87%	Net Selling	Net Selling
TFFP	TFF PHARMACEUTICALS INC	United States	$8.87M	2,519,220	3.17%	96.83%	Net Buying
IGMS	IGM BIOSCIENCES INC	United States	$553.18M	58,786,588	37.27%	54.48%	Net Buying	Net Buying
OCUP	OCUPHIRE PHARMA INC	United States	$43.67M	24,813,370	1.23%	98.77%	Net Buying	Net Buying
SEER	SEER INC	United States	$115.94M	64,773,180	54.70%	45.30%	Net Buying	Net Selling
AXSM	AXSOME THERAPEUTICS INC	United States	$3.23B	47,374,375	71.00%	29.00%	Net Selling	Net Buying
MIRM	MIRUM PHARMACEUTICALS INC	United States	$1.12B	47,003,329	48.94%	51.06%	Net Buying	Net Selling
NVO	NOVO NORDISK A S	Denmark	$558.79B	4,510,000,000	6.84%	0.00%
KRYS	KRYSTAL BIOTECH INC	United States	$4.80B	28,292,616	75.55%	24.45%	Net Selling	Net Selling
REGN	REGENERON PHARMACEUTICALS INC	United States	$98.63B	109,761,896	69.39%	30.61%	Net Selling	Net Buying
FULC	FULCRUM THERAPEUTICS INC	United States	$455.84M	61,935,171	64.02%	35.98%	Net Buying	Net Buying
AGIO	AGIOS PHARMACEUTICALS INC	United States	$1.64B	56,194,847	75.09%	24.91%	Net Selling	Net Selling
RNA	AVIDITY BIOSCIENCES INC	United States	$1.91B	79,719,473	82.47%	17.53%	Net Selling	Net Selling
TECH	BIO-TECHNE CORP	United States	$10.30B	157,191,685	97.66%	2.34%	Net Buying	Net Selling
IDYA	IDEAYA BIOSCIENCES INC	United States	$3.09B	74,560,273	88.70%	10.03%	Net Selling	Net Selling
IMMP	IMMUTEP LTD	Australia	$274.62M	1,188,834,559	0.17%	0.00%
CLGN	COLLPLANT BIOTECHNOLOGIES LTD	Israel	$59.27M	11,452,672	12.49%	0.00%
JAZZ	JAZZ PHARMACEUTICALS PLC	Ireland	$6.91B	62,345,283	26.94%	73.06%	Net Selling	Net Selling
VYNE	VYNE THERAPEUTICS INC	United States	$36.23M	14,098,888	23.19%	76.81%	Net Buying	Net Selling
PRTA	PROTHENA CORP PUBLIC LTD CO	Ireland	$1.18B	53,720,455	53.06%	46.94%	Net Buying	Net Buying
VTGN	VISTAGEN THERAPEUTICS INC	United States	$128.37M	27,025,209	38.92%	61.08%	Net Buying
INM	INMED PHARMACEUTICALS INC	Canada	$1.93M	6,056,970	13.28%	11.17%	Net Buying	Net Buying
ADAG	ADAGENE INC	China	$114.70M	55,145,839	12.92%	0.00%
GNFT	GENFIT SA	France	$175.42M	49,834,983	1.27%	0.00%
ARCT	ARCTURUS THERAPEUTICS HOLDINGS INC	United States	$788.89M	26,915,243	87.10%	12.90%	Net Selling	Net Selling
ALGS	ALIGOS THERAPEUTICS INC	United States	$67.72M	75,668,521	54.25%	45.75%	Net Buying
LPCN	LIPOCINE INC	United States	$28.47M	5,315,830	5.77%	94.23%	Net Buying
KZR	KEZAR LIFE SCIENCES INC	United States	$58.90M	72,801,359	67.83%	21.82%	Net Buying
ORMP	ORAMED PHARMACEUTICALS INC	United States	$98.06M	40,519,160	12.73%	46.42%
MDWD	MEDIWOUND LTD	Israel	$147.55M	9,221,764	27.28%	0.00%
XCUR	EXICURE INC	United States	$5.26M	8,648,307	0.89%	99.11%	Net Selling	Net Selling
ZLAB	ZAI LAB LTD	China	$1.41B	992,087,430	4.15%	1.96%	Net Buying	Net Buying
QURE	UNIQURE NV	Netherlands	$226.75M	47,838,275	78.37%	13.99%	Net Selling	Net Selling
LIFE	ATYR PHARMA INC	United States	$115.18M	67,750,024	60.86%	22.55%	Net Buying	Net Selling
GBIO	GENERATION BIO CO	United States	$245.97M	66,477,111	63.25%	36.75%	Net Buying	Net Selling
MORF	MORPHIC HOLDING INC	United States	$1.48B	50,037,229	64.32%	35.68%	Net Buying	Net Buying
GLPG	GALAPAGOS NV	Belgium	$1.96B	65,897,071	30.01%	0.00%
VRTX	VERTEX PHARMACEUTICALS INC	United States	$102.64B	258,307,816	90.91%	1.48%	Net Selling	Net Selling
ANIX	ANIXA BIOSCIENCES INC	United States	$100.80M	31,899,800	13.83%	84.70%	Net Buying	Net Buying
LEGN	LEGEND BIOTECH CORP	United States	$9.41B	363,822,069	23.61%	0.00%
SAGE	SAGE THERAPEUTICS INC	United States	$920.83M	60,106,687	71.61%	28.39%	Net Selling
PTGX	PROTAGONIST THERAPEUTICS INC	United States	$1.55B	58,274,998	79.94%	20.06%	Net Selling	Net Selling
MRUS	MERUS NV	Netherlands	$2.39B	57,878,284	87.00%	13.00%	Net Selling
SNSE	SENSEI BIOTHERAPEUTICS INC	United States	$25.20M	25,070,980	11.82%	71.99%	Net Selling	Net Selling
BOLT	BOLT BIOTHERAPEUTICS INC	United States	$43.08M	38,127,740	54.74%	45.26%	Net Selling
ACIU	AC IMMUNE SA	Switzerland	$249.98M	99,197,829	29.88%	0.00%
XBIO	XENETIC BIOSCIENCES INC	United States	$6.38M	1,540,684	0.42%	99.58%
FATE	FATE THERAPEUTICS INC	United States	$559.70M	99,237,508	61.86%	38.14%	Net Buying	Net Selling
ABIO	ARCA BIOPHARMA INC	United States	$46.11M	14,501,143	4.98%	95.02%
SLGL	SOL-GEL TECHNOLOGIES LTD	Israel	$23.99M	27,857,620	28.59%	0.00%
FUSN	FUSION PHARMACEUTICALS INC	Canada	$1.80B	84,692,585	71.20%	28.80%
ARGX	ARGENX SE	Belgium	$22.27B	59,194,488	55.29%	0.00%
CDTX	CIDARA THERAPEUTICS INC	United States	$74.61M	90,433,777	25.63%	15.98%	Net Selling	Net Selling
BCYC	BICYCLE THERAPEUTICS PLC	United Kingdom	$929.23M	42,586,185	61.51%	38.49%	Net Selling	Net Selling
ZVRA	ZEVRA THERAPEUTICS INC	United States	$207.79M	43,426,186	29.20%	27.84%	Net Buying
CLNN	CLENE INC	United States	$42.51M	128,430,098	9.06%	52.86%	Net Buying
MRKR	MARKER THERAPEUTICS INC	United States	$39.53M	8,902,897	1.30%	98.70%
PHAR	PHARMING GROUP NV	Netherlands	$723.42M	671,073,243	0.00%	0.00%
VERV	VERVE THERAPEUTICS INC	United States	$611.26M	83,619,279	62.25%	37.75%	Net Buying	Net Selling
TRAW	TRAWS PHARMA INC	United States	$15.11M	21,040,645	5.95%	94.05%	Net Selling	Net Selling
JANX	JANUX THERAPEUTICS INC	United States	$2.68B	51,660,060	54.14%	45.86%	Net Buying
EDIT	EDITAS MEDICINE INC	United States	$497.43M	81,813,850	64.04%	35.96%	Net Selling	Net Selling
ALT	ALTIMMUNE INC	United States	$535.26M	70,895,286	34.70%	65.30%	Net Selling	Net Selling
RYTM	RHYTHM PHARMACEUTICALS INC	United States	$2.41B	60,140,495	87.97%	12.03%	Net Selling	Net Selling
EYPT	EYEPOINT PHARMACEUTICALS INC	United States	$1.06B	49,830,792	20.59%	79.41%	Net Selling	Net Selling
ITOS	ITEOS THERAPEUTICS INC	United States	$421.52M	35,843,131	62.37%	37.63%	Net Selling
SRPT	SAREPTA THERAPEUTICS INC	United States	$11.10B	93,855,410	73.88%	26.12%	Net Buying	Net Selling
SPRB	SPRUCE BIOSCIENCES INC	United States	$29.05M	41,149,160	63.59%	36.41%	Net Selling	Net Selling
SPRY	ARS PHARMACEUTICALS INC	United States	$891.67M	96,501,554	43.78%	56.22%	Net Buying	Net Buying
BGNE	BEIGENE LTD	Cayman Islands	$14.49B	1,359,513,224	3.31%	34.70%	Net Selling	Net Selling
RVMD	REVOLUTION MEDICINES INC	United States	$5.85B	164,690,408	89.46%	10.54%	Net Selling	Net Selling
PLRX	PLIANT THERAPEUTICS INC	United States	$816.24M	60,239,176	70.74%	29.26%	Net Selling	Net Selling
ZYME	ZYMEWORKS INC	Canada	$641.47M	70,568,222	61.32%	38.68%	Net Buying
ARDX	ARDELYX INC	United States	$1.58B	232,686,008	38.00%	62.00%	Net Selling	Net Selling
IMTX	IMMATICS NV	Germany	$880.44M	84,657,789	58.58%	0.00%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -28.76% over the past year, underperforming other biotech stocks by -5 percentage points.

Incyte has an average 1 year price target of $73.92, an upside of 38.34% from Incyte's current stock price of $53.43.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Incyte, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -11.48% over the past year, overperforming other biotech stocks by 13 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $38.00, an upside of 28.73% from Harmony Biosciences Holdings's current stock price of $29.52.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 42.86% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 14.29% have issued a Sell rating, and 14.29% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 4.04% over the past year, overperforming other biotech stocks by 28 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 148.79% from Voyager Therapeutics's current stock price of $8.24.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 14.21%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)

Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 53.85%, which is 40 percentage points higher than the biotech industry average of 14.21%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)

Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.11%, which is -13 percentage points lower than the biotech industry average of 14.21%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.9% in the last day, and down -4.04% over the last week. Marinus Pharmaceuticals was the among the top losers in the biotechnology industry, dropping -82.71% yesterday.

Marinus Pharmaceuticals shares are trading lower after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -22.73% in the past year. It has overperformed other stocks in the biotech industry by 1 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 4.04% in the past year. It has overperformed other stocks in the biotech industry by 28 percentage points.

3. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -28.76% in the past year. It has underperformed other stocks in the biotech industry by -5 percentage points.

Are biotech stocks a good buy now?

49.13% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 80.44% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.94x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.